Landscape and Treatment Options of Shapeshifting Small Cell Lung Cancer

Author:

Gu Yijun1,Benavente Claudia A.123ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, USA

2. Department of Developmental and Cell Biology, University of California, Irvine, CA 92697, USA

3. Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA

Abstract

Small cell lung cancer (SCLC) is a deadly neuroendocrine malignancy, notorious for its rapid tumor growth, early metastasis, and relatively “cold” immune environment. Only standard chemotherapies and a few immune checkpoint inhibitors have been approved for SCLC treatment, revealing an urgent need for novel therapeutic approaches. Moreover, SCLC has been recently recognized as a malignancy with high intratumoral and intertumoral heterogeneity, which explains the modest response rate in some patients and the early relapse. Molecular subtypes defined by the expression of lineage-specific transcription factors (ASCL1, NEUROD1, POU2F3, and, in some studies, YAP1) or immune-related genes display different degrees of neuroendocrine differentiation, immune cell infiltration, and response to treatment. Despite the complexity of this malignancy, a few biomarkers and targets have been identified and many promising drugs are currently undergoing clinical trials. In this review, we integrate the current progress on the genomic landscape of this shapeshifting malignancy, the characteristics and treatment vulnerabilities of each subtype, and promising drugs in clinical phases.

Funder

American Lung Association

Publisher

MDPI AG

Reference104 articles.

1. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Bray;CA A Cancer J. Clin.,2018

2. (2021, May 04). The American Cancer Society Medical and Editorial Content Team What Is Lung Cancer?|Types of Lung Cancer. Available online: https://www.cancer.org/cancer/lung-cancer/about/what-is.html.

3. Cittolin-Santos, G.F., Knapp, B., Ganesh, B., Gao, F., Waqar, S., Stinchcombe, T.E., Govindan, R., and Morgensztern, D. (2024). The Changing Landscape of Small Cell Lung Cancer. Cancer.

4. Neuroendocrine Tumors of the Lung;Demes;Cancers,2012

5. Recent Progress in Mapping the Emerging Landscape of the Small Cell Lung Cancer Genome;Kim;Exp. Mol. Med.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3